共查询到20条相似文献,搜索用时 32 毫秒
1.
Lena Innala Ewa Berglin Bozena M?ller Lotta Ljung Torgny Smedby Anna S?dergren Staffan Magnusson Solbritt Rantap??-Dahlqvist Solveig W?llberg-Jonsson 《Arthritis research & therapy》2014,16(2):R94
Introduction
Disease activity, severity and comorbidity contribute to increased mortality in patients with rheumatoid arthritis (RA). We evaluated the impact of age at disease onset on prognostic risk factors and treatment in patients with early disease.Methods
In this study, 950 RA patients were followed regularly from the time of inclusion (<12 months from symptom onset) for disease activity (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), tender and/or swollen joints, Visual Analogue Scale pain and global scores, and Disease Activity Score in 28 joints (DAS28)) and function (Health Assessment Questionnaire (HAQ)). Disease severity, measured on the basis of radiographs of the hands and feet (erosions based on Larsen score), extraarticular disease, nodules, and comorbidities and treatment (disease-modifying antirheumatic drugs (DMARDs), corticosteroids, biologics and nonsteroidal anti-inflammatory drugs) were recorded at the time of inclusion and at 5 years. Autoantibodies (rheumatoid factor, antinuclear antibodies and antibodies against cyclic citrullinated peptides (ACPAs)) and genetic markers (human leucocyte antibody (HLA) shared epitope and protein tyrosine phosphatase nonreceptor type 22 (PTPN22)) were analysed at the time of inclusion. Data were stratified as young-onset RA (YORA) and late-onset RA (LORA), which were defined as being below or above the median age at the time of onset of RA (58 years).Results
LORA was associated with lower frequency of ACPA (P < 0.05) and carriage of PTPN22-T variant (P < 0.01), but with greater disease activity at the time of inclusion measured on the basis of ESR (P < 0.001), CRP (P < 0.01) and accumulated disease activity (area under the curve for DAS28 score) at 6 months (P < 0.01), 12 months (P < 0.01) and 24 months (P < 0.05), as well as a higher HAQ score (P < 0.01) compared with YORA patients. At baseline and 24 months, LORA was more often associated with erosions (P < 0.01 for both) and higher Larsen scores (P < 0.001 for both). LORA was more often treated with corticosteroids (P < 0.01) and less often with methotrexate (P < 0.001) and biologics (P < 0.001). YORA was more often associated with early DMARD treatment (P < 0.001). The results of multiple regression analyses supported our findings regarding the impact of age on chosen treatment.Conclusion
YORA patients were more frequently ACPA-positive than LORA patients. LORA was more often associated with erosions, higher Larsen scores, higher disease activity and higher HAQ scores at baseline. Nevertheless, YORA was treated earlier with DMARDs, whilst LORA was more often treated with corticosteroids and less often with DMARDs in early-stage disease. These findings could have implications for the development of comorbidities. 相似文献2.
Mewar D Coote A Moore DJ Marinou I Keyworth J Dickson MC Montgomery DS Binks MH Wilson AG 《Arthritis research & therapy》2006,8(4):R128-5
Several recent publications have established a strong association between anti-cyclic citrullinated peptide antibody (anti-CCP)-positive
rheumatoid arthritis (RA) and carriage of shared epitope (SE) alleles. Although anti-CCP have also been associated with more
severe RA, the issue of whether this is independent of rheumatoid factor (RF) has not been addressed. To identify associations
between RF, anti-CCP, SE status and radiological damage, we studied a large cross-sectional cohort with longstanding RA. Individuals
(n = 872) enrolled in the study all fulfilled the American College of Rheumatology criteria for RA, had a minimum disease duration
of 3 years, and at least one definite radiographic erosion was present in hands or feet. Radiographs were scored blind at
study entry by a single musculoskeletal radiologist using a modified Larsen's score. Anti-CCP and RF levels were determined
using enzyme-linked immunosorbent assay, and DRB1 typing was performed using polymerase chain reaction based methodology.
Both anti-CCP and RF levels were strongly associated with radiographic severity (P < 0.0001). In subgroups stratified for both anti-CCP and RF status, evidence of independent associations of both antibodies
with radiographic outcome was found (P < 0.0001). An association of SE alleles with radiographic severity was present only in RF-negative individuals. Anti-CCP
positivity was associated with SE status with evidence of a gene-dose effect, most markedly in RF-negative individuals (P < 0.01). Anti-CCP and RF status are independent severity factors for RA, with SE alleles playing at most a secondary role.
Our data support the view that previously described associations between SE and radiological severity, especially in RF-negative
patients, may be indirect and due to an association with anti-CCP. 相似文献
3.
Bruno Fautrel Benjamin Granger Bernard Combe Alain Saraux Francis Guillemin Xavier Le Loet 《Arthritis research & therapy》2012,14(6):R249
Introduction
Early rheumatoid arthritis (RA) patients may show rapid radiographic progression (RRP) despite rapid initiation of synthetic disease-modifying anti-rheumatic drugs (DMARDs). The present study aimed to develop a matrix to predict risk of RRP despite early DMARD initiation in real life settings.Methods
The ESPOIR cohort included 813 patients from the community with early arthritis for < 6 months; 370 patients had early RA and had received methotrexate or leflunomide during the first year of follow-up. RRP was defined as an increase in the van der Heijde-modified Sharp score (vSHS) ≥ 5 points at 1 year. Determinants of RRP were examined first by bivariate analysis, then multivariate stepwise logistic regression analysis. A visual matrix model was then developed to predict RRP in terms of patient baseline characteristics.Results
We analyzed data for 370 patients. The mean Disease Activity Score in 28 joints was 5.4 ± 1.2, 18.1% of patients had typical RA erosion on radiographs and 86.4% satisfied the 2010 criteria of the American College of Rheumatology/European League Against Rheumatism. During the first year, mean change in vSHS was 1.6 ± 5.5, and 41 patients (11.1%) showed RRP. A multivariate logistic regression model enabled the development of a matrix predicting RRP in terms of baseline swollen joint count, C-reactive protein level, anti-citrullinated peptide antibodies status, and erosions seen on radiography for patients with early RA who received DMARDs.Conclusions
The ESPOIR matrix may be a useful clinical practice tool to identify patients with early RA at high risk of RRP despite early DMARD initiation. 相似文献4.
Jung Hee Koh Seung Min Jung Jennifer Jooha Lee Kwi Young Kang Seung-Ki Kwok Sung-Hwan Park Ji Hyeon Ju 《PloS one》2015,10(8)
Objective
The relationship between mechanical stress and radiographic progression in rheumatoid arthritis (RA) is unclear. The assumption is that mechanical stress is greater in the dominant hand. Therefore, the aim of the present study was to compare the presence and progression of erosions and joint space narrowing (JSN) in the dominant and non-dominant hand.Methods
Data from 194 patients recently diagnosed with seropositive RA, and with hand radiographs taken at the time of diagnosis and at 2-year follow-up, were analyzed retrospectively. Radiographs were scored using the van der Heijde-modified Sharp Score (HSS) method. Each joint group within each hand was rated separately by two independent examiners in a double-blinded manner.Results
One hundred and ninety-four patients were enrolled (80% female, 88% positive rheumatoid factor, 92% positive anti-citrullinated protein antibody, and 95.4% right-handed). The baseline, follow-up erosion and JSN HSS were significantly higher in the dominant hand than in the non-dominant hand. The annual rate of radiographic progression was also higher in the dominant hand. The erosive progression in the wrist joints varied significantly according to handedness, but the erosion in the proximal interphalangeal joints and metacarpophalangeal joints was similar in both hands. The radiographic progression was associated with the dominant hand, an abnormal baseline C-reactive protein level, and joint damage at baseline. There was no significant difference in bone mineral density between the right and left hands.Conclusion
Radiological damage was worse and progressed faster in the dominant hand, suggesting that mechanical stress is associated with radiographic joint damage in early and active RA. 相似文献5.
Marotte H Pallot-Prades B Grange L Gaudin P Alexandre C Miossec P 《Arthritis research & therapy》2007,9(3):R61
The goal of the present study was to record changes in bone mineral density (BMD) and markers of bone turnover in patients
with rheumatoid arthritis (RA) who were treated with methotrexate combined (or not combined) with infliximab. Included were
90 patients with RA who required anti-TNF-α therapy with infliximab because of persistent active disease despite treatment
with methotrexate. The historical control group included 99 patients with RA who were treated with methotrexate at a time
when anti-TNF-α treatment was not yet available. Lumbar and femoral neck BMD was measured using dual energy X-ray absorptiometry
at baseline and 1 year later. Osteocalcin, C-terminal cross-linked telopeptide of type I collagen, parathyroid hormone and
25-hydroxycholecalciferol were measured in plasma at baseline and 1 year later. At 1 year BMD had decreased in the control
group at spine (P < 0.01) and femoral neck (P < 0.001). In contrast, BMD at spine and femoral neck did not change after 1 year of infliximab treatment. At the same time
point, no change in bone remodelling markers was observed. No association was observed between clinical response and changes
in BMD, indicating that even those who did not respond clinically did not lose bone over a 1-year period. These data confirm
the BMD decrease observed in RA patients treated with methotrexate alone. This bone loss was prevented by infliximab therapy.
Importantly, this beneficial effect was also observed in apparent nonresponders. 相似文献
6.
Maurizio Cutolo Cornelia M Spies Frank Buttgereit Sabrina Paolino Carmen Pizzorni 《Arthritis research & therapy》2014,16(Z2):S1
The management of rheumatoid arthritis (RA) is primarily based on the use of disease-modifying antirheumatic drugs (DMARDs), mainly comprising synthetic chemical compounds (that is, methotrexate or leflunomide) and biological agents (tumor necrosis factor inhibitors or abatacept). On the other hand, glucocorticoids (GCs), used for decades in the treatment of RA, are effective in relieving signs and symptoms of the disease, but also interfere with radiographic progression, either as monotherapy or in combination with conventional synthetic DMARDs. GCs exert most of their biological effects through a genomic action, using the cytosolic GC receptor and then interacting with the target genes within target cells that can result in increased expression of regulatory - including anti-inflammatory - proteins (transactivation) or decreased production of proinflammatory proteins (transrepression). An inadequate secretion of GCs from the adrenal gland, in relation to stress and inflammation, seems to play an important role in the pathogenesis and disease progression of RA. At present there is clear evidence that GC therapy, especially long-term low-dose treatment, slows radiographic progression by at least 50% when given to patients with early RA, hence satisfying the conventional definition of a DMARD. In addition, long-term follow-up studies suggest that RA treatment strategies which include GC therapy may favorably alter the disease course even after their discontinuation. Finally, a low-dose, modified night-release formulation of prednisone, although administered in the evening (replacement therapy), has been developed to counteract the circadian (night) rise in proinflammatory cytokine levels that contributes to disease activity, and might represent the way to further optimize the DMARD activity exerted by GCs in RA. 相似文献
7.
Døhn UM Ejbjerg BJ Court-Payen M Hasselquist M Narvestad E Szkudlarek M Møller JM Thomsen HS Østergaard M 《Arthritis research & therapy》2006,8(4):R110-9
The objective of the study was, with multidetector computed tomography (CT) as the reference method, to determine whether
bone erosions in rheumatoid arthritis (RA) metacarpophalangeal (MCP) joints detected with magnetic resonance imaging (MRI)
and ultrasonography (US), but not with radiography, represent true erosive changes. We included 17 RA patients with at least
one, previously detected, radiographically invisible MCP joint MRI erosion, and four healthy control individuals. They all
underwent CT, MRI, US and radiography of the 2nd to 5th MCP joints of one hand on the same day. Each imaging modality was
evaluated for the presence of bone erosions in each MCP joint quadrant. In total, 336 quadrants were examined. The sensitivity,
specificity and accuracy, respectively, for detecting bone erosions (with CT as the reference method) were 19%, 100% and 81%
for radiography; 68%, 96% and 89% for MRI; and 42%, 91% and 80% for US. When the 16 quadrants with radiographic erosions were
excluded from the analysis, similar values for MRI (65%, 96% and 90%) and US (30%, 92% and 80%) were obtained. CT and MRI
detected at least one erosion in all patients but none in control individuals. US detected at least one erosion in 15 patients,
however, erosion-like changes were seen on US in all control individuals. Nine patients had no erosions on radiography. In
conclusion, with CT as the reference method, MRI and US exhibited high specificities (96% and 91%, respectively) in detecting
bone erosions in RA MCP joints, even in the radiographically non-erosive joints (96% and 92%). The moderate sensitivities
indicate that even more erosions than are seen on MRI and, particularly, US are present. Radiography exhibited high specificity
(100%) but low sensitivity (19%). The present study strongly indicates that bone erosions, detected with MRI and US in RA
patients, represent a loss of calcified tissue with cortical destruction, and therefore can be considered true bone erosions. 相似文献
8.
Seth D Seegobin Margaret HY Ma Chanaka Dahanayake Andrew P Cope David L Scott Cathryn M Lewis Ian C Scott 《Arthritis research & therapy》2014,16(1):R13
Introduction
UK guidelines recommend that all early active rheumatoid arthritis (RA) patients are offered combination disease-modifying antirheumatic drugs (DMARDs) and short-term corticosteroids. Anti-citrullinated protein antibody (ACPA)-positive and ACPA-negative RA may differ in their treatment responses. We used data from a randomized controlled trial - the Combination Anti-Rheumatic Drugs in Early RA (CARDERA) trial - to examine whether responses to intensive combination treatments in early RA differ by ACPA status.Methods
The CARDERA trial randomized 467 early active RA patients to receive: (1) methotrexate, (2) methotrexate/ciclosporin, (3) methotrexate/prednisolone or (4) methotrexate/ciclosporin/prednisolone in a factorial-design. Patients were assessed every six months for two years. In this analysis we evaluated 431 patients with available ACPA status. To minimize multiple testing we used a mixed-effects repeated measures ANOVA model to test for an interaction between ACPA and treatment on mean changes from baseline for each outcome (Larsen, disease activity scores on a 28-joint count (DAS28), Health Assessment Questionnaire (HAQ), EuroQol, SF-36 physical component summary (PCS) and mental component summary (MCS) scores). When a significant interaction was present, mean changes in outcomes were compared by treatment group at each time point using t-tests stratified by ACPA status. Odds ratios (ORs) for the onset of new erosions with treatment were calculated stratified by ACPA.Results
ACPA status influenced the need for combination treatments to reduce radiological progression. ACPA-positive patients had significant reductions in Larsen score progression with all treatments. ACPA-positive patients receiving triple therapy had the greatest benefits: two-year mean Larsen score increases comprised 3.66 (95% confidence interval (CI) 2.27 to 5.05) with triple therapy and 9.58 (95% CI 6.76 to 12.39) with monotherapy; OR for new erosions with triple therapy versus monotherapy was 0.32 (95% CI 0.14 to 0.72; P = 0.003). ACPA-negative patients had minimal radiological progression irrespective of treatment. Corticosteroid’s impact on improving DAS28/PCS scores was confined to ACPA-positive RA.Conclusions
ACPA status influences the need for combination DMARDs and high-dose tapering corticosteroids in early RA. In CARDERA, combination therapy was only required to prevent radiological progression in ACPA-positive patients; corticosteroids only provided significant disease activity and physical health improvements in ACPA-positive disease. This suggests ACPA is an important biomarker for guiding treatment decisions in early RA.Trial registration
Current Controlled Trials ISRCTN32484878 相似文献9.
目的:探讨血清抗角蛋白抗体谱对类风湿关节炎预后的判断价值。方法:选择早期、活动性类风湿关节炎患者82例(病程≤6个月),分为病例组(抗角蛋白抗体谱阳性组,n=39)和对照组(抗角蛋白抗体谱阴性组,n=43),均给予相同的治疗方案,在治疗前、治疗后12个月、治疗后24个月分别记录全部患者的关节肿胀数、关节压痛数、晨僵时间和红细胞沉降率的变化,通过治疗前及治疗后24个月分别记录手足X线正位片、Sharp评分和DAS28评分标准进行评价。结果:治疗12个月后病例组临床指标的改善较对照组差(P〈0.01);24个月后病例组X线分期变化情况进展明显大于对照组(P〈0.01)。结论:抗角蛋白抗体阳性谱患者的临床指标和影像学变化情况较抗角蛋白抗体谱阴性患者对治疗的反应较差,更易发生关节破坏。 相似文献
10.
Background: The histopathologic characteristics of the antral erosions, and a comparison with samples systematically collected from the background antral mucosa, have not been studied previously. Similarly, unknown is the association of these features with suspected etiological factors and chronicity of erosion. Material and Methods: We studied 117 patients with gastric erosions in the absence of peptic ulcer disease. With 28 patients available for a follow‐up 19 years later, sites of erosions and background mucosa were biopsied and histopathology of both independently assessed at both visits. Helicobacter pylori status was examined from the biopsies taken in the initial and follow‐up gastroscopies. Only subjects originally displaying antral erosions were included. The presence of Herpes simplex virus (HSV) antibodies was analyzed and use of nonsteroidal anti‐inflammatory drug (NSAID) was inquired. Results: Initially, the inflammation was more active in the region of erosions than elsewhere in antral mucosa. More active inflammation in the erosion was associated with HSV seropositivity, Helicobacter pylori infection, and the recent use of NSAIDs. In the follow‐up visit, antral erosions were present in 38% (3/8) of Helicobacter pylori negatives and in 35% (7/20) of positives (p = ns). The Helicobacter pylori positive subjects with chronic or recurrent erosions had initially higher scores of neutrophils compared to subjects with nonrecurrent or nonchronic erosions (2.7 ± 0.5 vs 1.2 ± 1.0; p = .002). Conclusions: Focally enhanced inflammation is characteristic for gastric erosions. This focal inflammation was associated with HSV seropositivity or NSAID use suggesting that such inflammation may be important in the pathogenesis of gastric antral erosions. Highly active inflammation in the erosions associates with their chronicity. 相似文献
11.
Javier Narváez César Díaz-Torné Berta Magallares Maria Victoria Hernández Delia Reina Héctor Corominas Raimon Sanmartí Arturo Rodriguez de la Serna Josep Maria Llobet Joan M. Nolla 《PloS one》2015,10(4)
Objective
In agreement with EULAR recommendations, a DMARD in combination with a biotherapy is the reference treatment because of the superior long-term clinical and radiographic outcomes. Methotrexate (MTX) is the cornerstone of combination therapy but is in some cases contra-indicated or poorly tolerated. This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting.Methods
We performed an ambispective review of 91 patients with active RA who were routinely treated with TCZ plus MTX or LEF. A comparative study between the two combinations of treatment was performed at 6 months of follow-up considering 3 outcomes: improvement of RA disease activity, evolution of functional disability, and tolerability and side effect profile.Results
Of the 91 patients, 62 received TCZ with MTX and 29 received TCZ with LEF. Eighty-one patients were followed for 6 months, and the remaining 10 patients discontinued treatment due to serious adverse events. At baseline, there were no significant differences between the groups in terms of the main clinical and laboratory data or in the number of previous DMARDs and biological agents used. At 6 months, there were no significant differences between the combinations in terms of disease activity and functional disability. Serious adverse events occurred in 11% and 10% of the patients treated in combination with MTX and LEF, respectively.Conclusion
Our preliminary data support the argument that LEF is an effective and safe (equivalent) alternative to MTX for combination treatment with TCZ. 相似文献12.
Yocum D 《Arthritis research & therapy》2004,6(Z2):S24-S30
Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which structural joint damage can continue to develop even in the face of symptomatic relief. Before the introduction of biologic agents, the management of RA involved the use of disease-modifying antirheumatic drugs (DMARDs) early in the course of disease. This focus on early treatment, combined with the availability of the anti-TNF agents, has contributed to a shift in treatment paradigms favoring the early and timely use of DMARDs with biologic therapies. Improvement in symptom control does not always equate to a reduction in disease progression or disability. With the emergence of structure-related outcome measures as the primary means for assessing the effectiveness of antirheumatic agents, the regular use of X-rays is recommended for the continued monitoring and evaluation of patients. In addition to the control of symptoms and improvement in physical function, a reduction in erosions and joint-space narrowing should be considered among the goals of therapy, leading to a better quality of life. Adherence to therapy is an important element in optimizing outcomes. Durability of therapy with anti-TNF agents as reported from clinical trials can also be achieved in the clinical setting. Concomitant methotrexate therapy might be important in maintaining TNF antagonist therapy in the long term. Overall, the TNF antagonists have led to improvements in clinical and radiographic outcomes in patients with RA, especially those who have failed to show a complete response to methotrexate. 相似文献
13.
Kapetanovic MC Larsson L Truedsson L Sturfelt G Saxne T Geborek P 《Arthritis research & therapy》2006,8(4):R131-7
In the present study we evaluated the impact of baseline antinuclear antibody (ANA) status and use of methotrexate on development
of infliximab-related infusion reactions in patients with rheumatoid arthritis (RA) or spondylarthropathies (SpAs), including
psoriatic arthritis. All patients with RA (n = 213) or SpA (n = 76) treated with infliximab during the period 1999–2005 at the Department of Rheumatology in Lund, Sweden were included.
ANAs were present in 28% and 25% of RA and SpA patients, respectively. Because of differences in baseline characteristics,
we used a binary logistic regression model to calculate odds ratios (ORs), adjusting for age, sex and prednisolone dosage.
Altogether 21% of patients with RA and 13% of patients with SpA developed infusion reactions (P = 0.126). The OR for development of infusion reactions in RA patients with baseline ANA positivity alone was 2.1. Infliximab
without methotrexate and infliximab as monotherapy were associated with ORs of 3.1 and 3.6, respectively. Combining infliximab
without methotrexate and ANA positivity yielded an OR for infusion reaction of 4.6. Lower age at disease onset and longer
disease duration were associated with infusion reactions (P = 0.012 and P = 0.036, respectively), but age, sex, C-reactive protein, erythrocyte sedimentation rate, Health Assessment Questionnaire
and Disease Activity Score-28 at baseline were not. No predictors of infusions reactions were identified in SpA patients.
RA patients treated with infliximab without methotrexate, and who are positive at baseline for ANAs are at increased risk
for developing infliximab-related infusion reactions. 相似文献
14.
Meyer O Nicaise-Roland P Santos MD Labarre C Dougados M Goupille P Cantagrel A Sibilia J Combe B 《Arthritis research & therapy》2006,8(2):R40-8
The objective of this study was to evaluate the potential of serially determined anti-cyclic citrullinated peptide (CCP) antibodies
for predicting structural joint damage in patients with early rheumatoid arthritis (RA), compared to a single baseline determination.
Ninety-nine RA patients with disease durations of less than one year and no history of disease-modifying antirheumatic drug
therapy were followed prospectively for at least five years. Anti-CCP2 concentrations were measured using a second-generation
ELISA. Sharp scores as modified by van der Heijde were determined on hand and foot radiographs. Anti-CCP2 antibodies were
detected in 55.5% of patients at baseline and 63.6% at any time during the first three years. Presence of anti-CCP2 at any
time during the first three years was associated with radiographic damage at baseline (odds ratio (OR), 3.66; 95% confidence
interval (95% CI) 0.99–13.54) and with five year progression of the total Sharp score (OR, 3.17; 95% CI, 1.3–7.7), erosion
score (OR, 5.3; 95% CI, 1.4–19.2) and joint space narrowing score (OR, 2.8; 95% CI, 1.15–6.8). The presence of anti-CCP2 or
IgM RF at baseline did not predict these outcomes. Patients with negative anti-CCP2 tests throughout follow-up had less radiographic
progression than patients with increasing anti-CCP2 concentrations; they did not differ from patients with decreasing anti-CCP2
antibody levels. HLADRB1* typing showed that progression of the mean modified Sharp score was not correlated with the presence
of the shared epitope alleles. In conclusion, serially determined anti-CCP2 antibodies during the first three years of follow-up
performs better than baseline determination for predicting radiographic progression in patients with early RA. 相似文献
15.
Paula I Burgos Zenoria L Causey Ashutosh Tamhane James M Kelley Elizabeth E Brown Laura B Hughes Maria I Danila Amalia van Everdingen Doyt L Conn Beth L Jonas Leigh F Callahan Edwin A Smith Richard D Brasington Jr Larry W Moreland Désirée M van der Heijde Graciela S Alarcón S Louis Bridges Jr 《Arthritis research & therapy》2010,12(3):1-7
Introduction
To determine whether IL4R single-nucleotide polymorphisms (SNPs) rs1805010 (I50V) and rs1801275 (Q551R), which have been associated with disease severity in rheumatoid arthritis (RA) patients of European ancestry, relate to the presence of rheumatoid nodules and radiographic erosions in African Americans.Methods
Two IL4R SNPs, rs1805010 and rs1801275, were genotyped in 749 patients from the Consortium for Longitudinal Evaluation of African-Americans with Early Rheumatoid Arthritis (CLEAR) registries. End points were rheumatoid nodules defined as present either by physical examination or by chest radiography and radiographic erosions (radiographs of hands/wrists and feet were scored using the modified Sharp/van der Heijde system). Statistical analyses were performed by using logistic regression modeling adjusted for confounding factors.Results
Of the 749 patients with RA, 156 (20.8%) had rheumatoid nodules, with a mean age of 47.0 years, 84.6% female gender, and median disease duration of 1.9 years. Of the 461 patients with available radiographic data, 185 (40.1%) had erosions (score >0); their mean age was 46.7 years; 83.3% were women; and median disease duration was 1.5 years. Patients positive for HLA-DRB1 shared epitope (SE) and autoantibodies (rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)) had a higher risk of developing rheumatoid nodules in the presence of the AA and AG alleles of rs1801275 (odds ratio (OR)adj = 8.08 (95% confidence interval (CI): 1.60-40.89), P = 0.01 and ORadj = 2.97 (95% CI, 1.08 to 8.17), P = 0.04, respectively). Likewise, patients positive for the HLA-DRB1 SE and RF alone had a higher risk of developing rheumatoid nodules in presence of the AA and AG alleles of rs1801275 (ORadj = 8.45 (95% CI, 1.57 to 45.44), P = 0.01, and ORadj = 3.57 (95% CI, 1.18 to 10.76), P = 0.02, respectively) and in the presence of AA allele of rs1805010 (ORadj = 4.52 (95% CI, 1.20 to 17.03), P = 0.03). No significant association was found between IL4R and radiographic erosions or disease susceptibility, although our statistical power was limited by relatively small numbers of cases and controls.Conclusions
We found that IL4R SNPs, rs1801275 and rs1805010, are associated with rheumatoid nodules in autoantibody-positive African-American RA patients with at least one HLA-DRB1 allele encoding the SE. These findings highlight the need for analysis of genetic factors associated with clinical RA phenotypes in different racial/ethnic populations. 相似文献16.
Capsoni F Sarzi-Puttini P Atzeni F Minonzio F Bonara P Doria A Carrabba M 《Arthritis research & therapy》2005,7(2):R250-R255
Neutrophils are known to be targets for the biological activity of tumour necrosis factor (TNF)-α in the pathogenensis of
rheumatoid arthritis (RA). Therefore, these cells may be among the targets of anti-TNF-α therapy. In this study we evaluated
the effect of therapy with adalimumab (a fully human anti-TNF-α mAb; dosage: 40 mg subcutaneously every other week) on certain
phenotypic and functional aspects of neutrophils obtained from 10 selected patients with RA and 20 healthy control individuals.
Peripheral blood neutrophils were obtained at baseline and during anti-TNF-α therapy (2, 6 and 12 weeks after the first administration
of adalimumab). All patients had been receiving a stable regimen of hydroxychloroquine, methotrexate and prednisone for at
least 3 months before and during the study. Baseline neutrophil chemotaxis was significantly decreased in RA patients when
compared with control individuals (P < 0.001). Two weeks after the first administration of adalimumab, chemotactic activity was completely restored, with no differences
noted between patients and control individuals; these normal values were confirmed 6 and 12 weeks after the start of anti-TNF-α
therapy. Phagocytic activity and CD11b membrane expression on neutrophils were similar between RA patients and control individuals;
no modifications were observed during TNF-α neutralization. The production of reactive oxygen species, both in resting and
PMA (phorbol 12-myristate 13-acetate)-stimulated cells, was significantly higher in RA patients at baseline (P < 0.05) and was unmodified by anti-TNF-α mAb. Finally, we showed that the activation antigen CD69, which was absent on control
neutrophils, was significantly expressed on neutrophils from RA patients at baseline (P < 0.001, versus control individuals); however, the molecule was barely detectable on cells obtained from RA patients during
adalimumab therapy. Because CD69 potentially plays a role in the pathogenesis of arthritis, our findings suggest that neutrophils
are among the targets of anti-TNF-α activity in RA and may provide an insight into a new and interesting mechanism of action
of anti-TNF-α mAbs in the control of inflammatory arthritis. 相似文献
17.
Some research evidence supports early aggressive treatment of rheumatoid arthritis (RA) using combination therapy with two
or more disease modifying anti-rheumatic drugs (DMARDs) plus steroids, or even DMARDs plus an anti-TNF. By contrast, conservatively
delayed DMARD monotherapy, given after non-steroidal anti-inflammatory drugs have failed, has been criticised. However, recent
long-term studies highlight the complexities in evaluating whether to abandon pyramidal treatment in favour of early DMARDs.
Although patients given early DMARD therapy show short-term benefits, longer-term results show no prolonged clinical advantages
from early DMARDs. By 5 years patients receiving early DMARDs had similar disease activity and comparable health assessment
questionnaire scores to patients who received DMARDs later in their disease course. X-ray progression was persistent and virtually
identical in both groups. These negative findings do not invalidate the case for early DMARD therapy, as it is gives sustained
reductions in disease activity in the early years of treatment without excessive risks from adverse effects. However, early
DMARDs alone do not adequately control RA in the longer term. This may require starting with very aggressive therapy or treating
patients more aggressively after early DMARD therapy has been initiated. 相似文献
18.
Scott DL 《Arthritis research & therapy》2004,6(1):15-18
Some research evidence supports early aggressive treatment of rheumatoid arthritis (RA) using combination therapy with two or more disease modifying anti-rheumatic drugs (DMARDs) plus steroids, or even DMARDs plus an anti-TNF. By contrast, conservatively delayed DMARD monotherapy, given after non-steroidal anti-inflammatory drugs have failed, has been criticised. However, recent long-term studies highlight the complexities in evaluating whether to abandon pyramidal treatment in favour of early DMARDs. Although patients given early DMARD therapy show short-term benefits, longer-term results show no prolonged clinical advantages from early DMARDs. By 5 years patients receiving early DMARDs had similar disease activity and comparable health assessment questionnaire scores to patients who received DMARDs later in their disease course. X-ray progression was persistent and virtually identical in both groups. These negative findings do not invalidate the case for early DMARD therapy, as it is gives sustained reductions in disease activity in the early years of treatment without excessive risks from adverse effects. However, early DMARDs alone do not adequately control RA in the longer term. This may require starting with very aggressive therapy or treating patients more aggressively after early DMARD therapy has been initiated. 相似文献
19.
Guyot P Taylor P Christensen R Pericleous L Poncet C Lebmeier M Drost P Bergman G 《Arthritis research & therapy》2011,13(6):R204
Introduction
The goal of this study was to compare the efficacy in terms of Health Assessment Questionnaire change from baseline (HAQ CFB), 50% improvement in American College of Rheumatology criterion (ACR-50) and Disease Activity Score in 28 joints (DAS28) defined remission (< 2.6) between abatacept and other biologic disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who have inadequate response to methotrexate (MTX-IR). 相似文献20.
Virginia Pascual-Ramos Irazú Contreras-Yá?ez Antonio R Villa Javier Cabiedes Marina Rull-Gabayet 《Arthritis research & therapy》2009,11(1):R26